MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40615-024-01973-7

Медицинская библиотека · Journal of racial and ethnic health disparities · 2024

The effect of race/ethnicity on cancer-specific mortality after trimodal therapy.

de Angelis Mario, Baudo Andrea, Siech Carolin, Jannello Letizia Maria Ippolita, Di Bello Francesco, Goyal Jordan A, Tian Zhe, Longo Nicola, de Cobelli Ottavio, Chun Felix K H, Saad Fred, Shariat Shahrokh F, Carmignani Luca, Gandaglia Giorgio, Moschini Marco, Montorsi Francesco, Briganti Alberto, Karakiewicz Pierre I

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Trimodal therapy (TMT) is the most validated bladder-sparing treatment for organ-confined urothelial carcinoma of the urinary bladder (OC UCUB, namely cT2N0M0). However, it is unknown if barriers to the use of TMT or cancer-specific mortality (CSM) differences exist according to race/ethnicity. We addressed this knowledge gap.

MATERIAL AND

METHODS

Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified OC UCUB patients aged from 18 to 85 treated with radical cystectomy (RC) or TMT. Temporal trends described TMT versus RC use over time. Subsequently, in the subgroup of TMT-treated patients, survival analyses consisting of Kaplan-Meier plots and multivariable Cox regression (MCR) models addressed CSM according to race/ethnicity.

RESULTS

Among 19,501 assessable patients, 15,336 (79%) underwent RC versus 4165 TMT (21%). Overall, of all races/ethnicities, 16,245 (83.3%) were White Americans, 1215 (6.3%) Hispanics, 1160 (5.9%) African Americans, and 881 (4.5%) Asian/Pacific Islanders. Among TMT-treated patients, 3460 (83.1%) were White Americans, 298 (7.1%) African Americans, 218 (5.3%) Hispanics, and 189 (4.5%) Asian/Pacific Islanders. The lowest rate of TMT use relative to RC and TMT patients was recorded in Hispanics (17.9%). Over time, TMT use increased in White Americans (EAPC: + 4.5%, p = 0.001) and Asians/Pacific Islanders (EAPC: + 5.2%, p = 0.003), but not in others. Kaplan-Meier analyses showed median CSM of 49 months, 41 months, and 34 months and not reached in White Americans, Hispanics, African Americans, and Asian/Pacific Islanders, respectively (p = 0.02). In MCR models, two race/ethnicity subgroups independently predicted either worse (African Americans, HR: 1.20, p = 0.02) or better CSM (Asian/Pacific Islanders, HR: 0.75, p = 0.02).

CONCLUSION

Race/ethnicity affects both access to TMT (lower access in Hispanics) as well as survival after TMT (better in Asians/Pacific Islanders and worse in African Americans).

Для цитирования: de Angelis Mario, Baudo Andrea, Siech Carolin, Jannello Letizia Maria Ippolita, Di Bello Francesco, Goyal Jordan A, Tian Zhe, Longo Nicola, de Cobelli Ottavio, Chun Felix K H, Saad Fred, Shariat Shahrokh F, Carmignani Luca, Gandaglia Giorgio, Moschini Marco, Montorsi Francesco, Briganti Alberto, Karakiewicz Pierre I. The effect of race/ethnicity on cancer-specific mortality after trimodal therapy.. Journal of racial and ethnic health disparities. 2024. DOI: 10.1007/s40615-024-01973-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.